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INTRODUCTION
Methotrexate has long been known as the agent of Choice for the treatment of gestational trophoblastic
disease and is, therefore, well known to gynaecologists and oncologists. Because of its therapeutic
effect in gestational trophoblastic disease, it appears well suited to eradicate trophoblastic tissue in
aberrant locations. A number of reports in the past few years indicate that the drug could be effective in
the management of unruptured ectopic pregnancies, thereby eliminating a surgical procedure which has
been considered so far the only available treatment for such cases. The side effects of therapy with
methotrexate are negligible. However, management with this antifolate requires very careful selection
of the patients to avoid the possible risks of a rupture and consequent bleeding in the abdomen. Early
detection of ectopic gestation facilitated by ultrasonography and sensitive assay systems for B-human
chorionic gonadotrophin is necessary for success of the therapy. Resolution of ectopics is monitored by
measuring plasma hCG levels during and after the treatment. Bypassing the risk, cost and morbidity of
surgery and preservation of fertility appear to be the major benefits of this treatment. Ectopic
pregnancy is a major problem in contemporary gynaecology. It occurs when the fertilized ovum
embeds in some site other than the uterine decidua. Nearly all ectopic implantations occur in the
fallopian tube but, to a very small extent, they can be in the ovary, cervix or the peritoneal cavity1. No
statistical data are available about its incidence in Pakistan. However, according to the information by
the Center for Disease Control in the United States, it appears to account for more than 1% of all
reported pregnancies in America, indicating that a large segment of the fertile population in the western
world is affected by this pathological condition2,3. Much higher incidence has been reported for
countries where pelvic infections are more common, for example in the West Indies it is 1 in 281. Since
pelvic infections are quite common in third world countries, ectopic pregnancy could be contributing
significantly to maternal mortality and infertility in Pakistan as well.
Traditional management
Salpingectomy which is often termed as a “radical approach” has been the traditional treatment for
tubal gestation4,5. Strome for the first time described a conservative surgical approach to the treatment
of ectopic pregnancy6. Development of microsurgical instrumentation has enabled a wide spread use of
conservative techniques. The rationale behind conservative approach is the preservation of reproductive
potential of the woman, although the repeat ectopic rates after radical and conservative management
remain the same 7-9. In the conservative treatment, the products of conception are carefully removed so
that there is minimal damage to the tubal tissue. Depending upon the condition of the tube (ruptured or
unruptured), location of gestation (interstitium, isthmus, ampulla) and the size of gestation, one of the
following surgical techniques is selected and performed by laparoscopy or laparotomy, linear salpingostomy, segmental resection, salpingectomy10. Laparoscopic approach is usually not recommended
when the maximum diameter of gestation is greater than 5 cm10. Post-operatively, an assessment of the
functional activity of the residual trophoblastic tissue is made by serial measurements of serum flhuman chorionic gonadotrophin (B-hCG) 11. There have been reports of persistent trophoblastic tissue
following conservative surgical management which subsequently necessitated salpingectomy for these
patients12-15. It was felt that perhaps a nonsurgical approach with an agent attacking the trophoblastic

tissue could have spared the fallopian tubes of these women. Since methotrexate (MTX) had been in
use for the treatment of gestational trophoblastic disease for nearly 3 decades 16, it was considered to
have a potential for pharmacological management of ectopic pregnancy.
MTX in the management of ectopic pregnancy
MDC therapy for resolution of ectopic pregnancy appeared attractive as this approach could spare
patient’s laparotomy and a tubal operation. Moreover, it was likely to result into less tissue trauma
which is critical for preservation of reproductive function. Tanaka et al. and Miyazaki et al. were the
first to report successful use of MIX in the management of interstitial and tubal pregnancies,
respectively17,18. This approach resulted in an abrupt termination of the pregnancy and subsequent
hysterosalpingography (HSG) revealed preservation of tubal patency. Development of sensitive
radioimmunoassay for B-hCG levels in serum provided gynaecologists with a useful tool to monitor
resolution of ectopic pregnancy following MIX therapy, because with the degeneration of trophoblastic
tissue, there was rapid disappearance of serum f3-hCG associated with clinical well- being of the
patient. During the past 8 years, there have been quite a few reports on systemic or local use of MIX in
the treatment of unruptured tubal pregnancies19-26. An analysis of these reports indicates that in more
than 200 tubal pregnancies treated with different MIX regimens, less than 5% of the patients required
surgical intervention because of tubal rupture27. This suggested a great promise for this relatively new
mode of treatment, however, the best method of MIX therapy is still being debated.
Modes of MIX treatment
In the treatment of ectopic pregnancy, MIXis given in several ways. Each mode of therapy has its
advantages and disadvantages.
1. Systemic administration
This treatment was adopted in the very first trials of MIX therapy in ectopic pregnancy17,21,23,24,28-30.
The anti-folate could be administered either intramuscularly or intravenously with or without
citrovorum factor. Two reports pertaining to the treatment of unruptured tubal gestations with MIX are
significant in this regard20-24. In one of these reports, Ichinoe et al. in 1987 treated 23 patients with
intramuscular injections of MIX (0.4 mg/kg/day for 5 days) every other week until the urinary hCG
levels dropped to 20 mIU/ml and achieved resolution of ectopic gestation in 22 patients within 6-47
days 20. Patency of the oviducts was established in 53% of the cases. Except for some changes in liver
function tests and slight bone marrow suppression, no untoward side effects were noticed. In another
study, Saueretal. in 1987 treated 21 patients with unruptured tubal pregnancy with a single course of 4
intramuscular injections of MIX (1 mg/kg on day 1,3, 5 and 7 after laparoscopy) followed by
intramuscular injections of citrovorum factor (0.1 mg/kg on day 2,4,6 and 8 after laparoscopy)24. All
ectopic pregnancies except one with intra-abdominal bleeding resolved without surgery within 5-60
days (median time for resolution was 27 days). Seventy-five percent of the patients (15 out of 20) had
patent tubes as revealed by HSG. Five out of the 21 patients showed symptoms of mild toxicity
(stomatitis, pleuritis and mildnausea) which resolved within 4 days of therapy termination. One of the
patients, in whom fetal heart activity was demonstrated by ultrasound, required laparotomy after MIX
treatment as bleeding started in her at the placental site. Therefore, it was concluded that ectopic
pregnancies that form fetal elements should not be managed medically. In remaining patients
elimination of major surgery and demonstration of tubal patency were the principal benefits of this
therapy. Recently, Stovall et al. have reported somewhat better results on a larger group of patients (n =
36) 23. These patients with unruptured tubal pregnancy were treated with MIX-citrovorum factor
protocol similar to the one used by Sauer et al. 24. However, they used individual dosage regimen based
on hCG and serum progesterone titers. This greatly reduced the total dose of chemotherapy required.
Due to this, the incidence of chemotherapeutic side effects was substantially reduced. Only one of 36
patients developed stomatitis which cleared within 24 hours after receiving the final dose of MIX.

Moreover hospitalization cost was significantly reduced as the patients were hospitalized only for
laparoscopy, whereas the protocol by Sauer et al. required hospital stay for nearly 7 days. This
improved regimen allowed patients to return to their normal schedules almost immediately. In all of the
above mentioned reports, MIX was administered either intravenously or intramuscularly. Based on the
success achieved by Barter et al. 31 in treating patients suffering from nonmetastatic gestational
trophoblastic disease with oral MIX, Patsner and Kenigsberg successfully treated a case of ectopic
pregnancy persisting after conservative tubal surgery with oral MIX therapy32. The drug was given in a
dose of 0.4 mg/kg/day for 5 days. It was well tolerated and no change in complete blood count or liver
function tests was observed. Stomatitis and mucositis did not occur and the patient became completely
asymptomatic after 1 week of this treatment. The major advantage of this treatmentwas that it could be
given in an outpatient setting.
2. Local administration
Reports of few cases of mild toxicity associated with systemic administration of MIX prompted
gynaecologists to look for more specific treatment of ectopic pregnancy. One approach was to inject
MIX directly into the gestational sac. The first report in this case appeared in 1987 when Feichtinger
and Kemeter successfully managed ectopic pregnancy by injecting MIX into the pregnancy sac under
vaginal ultrasound control33. More recently, Zakut et al. have treated ten patients with tubal pregnancy
by injecting MIX (12.5 mg diluted in 1.5 ml of distilled water) into the gestational sac under direct
laparoscopic vision followed by a dose of intramuscular MIX therapy (0.5 mg/kg) and folinic acid
“rescue” (0.1 mg/kg) for 5 days26. Complete resolution of ectopics was achieved in 8 of these 10
patients within 6-47 days. Tubal patency was demonstrated in 100% (seven) of the cases examined by
HSG. It was interesting to note that the two cases which did not respond to the treatment had ectopic
pregnancy sac measuring 3 cm x 3 cm or more, whereas all of the responding cases except one had the
sacs’ size smaller than that. Moreover, these two patients who were not responding to MTX treatment
had the highest hCG levels (3600 and 5700 mIU/ml) among the group suggesting that the size of the
gestational sac and the initial hCG levels can be important parameters for determining the expected
benefit of this therapy. Therefore, it appears that patients with large gestational sacs and with high
initial levels of hCG should be treated surgically rather than with MDC. Another approach for local
administration of MDC is injecting the thug (12.5 mg) directly into the fallopian tube. Pansky et al.
have recently treated 27 patients with unruptured tubal pregnancy with a single injection of the drug
into the ectopic site through the swollen tubal wall by means of a 15 cm long spinal needle (18 gauge)
introduced under laparoscopic guidance 22. Twenty-four of 27 patients responded to the treatment.
Hospital stay was considerably shortened and administration of the drug in this manner probably
facilitated achieving high tissue concentration of MDC in the affected tube, thereby avoiding the
systemic route and reducing the risk of adverse reactions. Similarly, Risquez et al. in France have
reported a novel procedure for intraluminal injection of MTX34. In this technique, selective retrograde
transcervical salpingography was carried out for the diagnosis of ectopic pregnancy. Tubal
catheterization not only facilitated the confirmation of the suspected tubal gestation but the therapeutic
dose of MDC (5-35 mg) could also be injected into the lumen of the fallopian tube. All 4 patients
treated this way had resolution of their ectopics. This simple procedure was well tolerated and there
were no side effects. Quite recently, Kooi and Kock in Netherlands have successfully treated 25
patients with local MDC injection after vasoconstriction of mesosalpinx with adrenalin27. They
selected a relatively high dose (100 mg) of the drug on the basis of reports that normal chorionic tissue
is analogous to malignant trophoblastic tissue which has been known to be quite resistant to MTX35. In
these patients, side effects of MDC and adrenaline were minimal. Whether this type of local treatment
with the thug ensures better chances of fertility in future still remains to be tested. Leeton and Davidson
in Australia followed a different approach for the management of ectopic pregnancy25. Under

ultrasound guidance, they punctured the amniotic sac with a 30 cm needle and aspirated the amniotic
fluid in avolume of 10-12 ml. When the amniotic sac completely collapsed, 50 mg MDC was injected
through the same needle into the sac in a volume of saline equal to the volume of the aspirate. This
technique was similar to follicular aspiration and flushing often used in many in vitro fertilization
oocyte-collection procedures36. Resorption and disorganization of the sac was noticed within two days
of the procedure. Plasma hCG levels became very low (C 10 mIU/ml) within a month and a half. There
were no symptoms of pain in the two patients treated this way. Spontaneous menstruation began in both
of them within 6 weeks of the treatment.
Mechanism of action of MTX
MDC is a folate antagonist which inhibits the enzyme dihydrofolate reductase and, thereby, blocks the
de novo pathway of DNA synthesis 37. Through this effect the drug inhibits cell replication and hence
exhibits its antitumor activity38. Since trophoblasts possess high proliferative activity due to increased
levels of dihydrofolate reductase, they quickly respond to inhibition by MDC. There is no single
explanation for the unique sensitivity of gestational trophoblastic tissue to this chemotherapy.
Bagshawe has proposed a combination of logarithmic chemotherapy “kill” and tissue autodestruction
as possible mechanisms 39. Rapid doubling time and immunologic responses directed at paternal or
other unique antigens are other factors that have received attention40.
Concluding remarks
All these reports indicate a great promise for this newprocedure in the management of ectopic
pregnancy. However, certain simple conclusions can be drawn from the published data. The most
important among these is that the criteria for selection of patients for this therapy must be quite
stringent as listed in Table I.

Certain absolute contraindications to MDC therapy are given in Table II.

It is noteworthy that the treatment has been possible only because of early detection of ectopic
gestations due to recent advances in diagnostic modalities. Moreover, the treatment when carried out
judiciously is quite effective and has minimal side effects and toxicity. When compared to the
traditional surgical procedures, there appears to be a better reproductive performance after this
therapy41. Selected cases of cornual or cervical pregnancy or those with residual trophoblastic tissue
which are usually difficult to manage surgically are good candidates for MDC therapy28,42-45. It is cost
effective in terms of reduction in hospitalization and convalescence time. It should be emphasized that
inspite of all its merits, MDC therapy appears appropriate for a select group of patients who fulfil
certain criteria and that surgery would still be mandatory when there is a risk of tubal rupture or when
intra-abdominal bleeding has taken place. In third world countries where catastrophic presentation of a
ruptured ectoyic gestation and hemoperitoneum is quite common surgery may still remain the major
treatment. Nevertheless, with the availability of ultrasound facility especially with the introduction of
vaginal probe and sensitive assay systems for hCG in major hospitals, it has now been possible to
diagnose this condition before a rupture occurs while the patient is only minimally symptomatic.
Accordingly, the treatment of ectopic pregnancy may shift from an immediate life saving intervention
into a more conservative method of management, aimed primarily at presenting fertility and reducing
the morbidity41. Use of MDC is one of these new conservative approaches which may achieve that
objective.
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